Interpretation on the <i>Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association</i>(<i>2022</i>)

LIANG Yun; WU Wenming; NIE Yongzhan; CHEN Jie

doi:10.12290/xhyxzz.2022-0607

Volume 14 Issue 1

Jan. 2023

Turn off MathJax

Article Contents

Abstract

References

Medical Journal of Peking Union Medical College Hospital > 2023 > 14(1): 94-100. > DOI: 10.12290/xhyxzz.2022-0607

LIANG Yun, WU Wenming, NIE Yongzhan, CHEN Jie. Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 94-100. DOI: 10.12290/xhyxzz.2022-0607

Citation:

PDF (468 KB)

Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)

LIANG Yun^{1, 2},
WU Wenming^3, ,,
NIE Yongzhan^4, ,,
CHEN Jie^{1, 2, ,}

1.
Center for Neuroendocrine Tumors, Department of Head & Neck Tumors and Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai 200032, China
2.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
3.
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
4.
Department of Gastroenterology, Xijing Hospital, Air Force Medical University, Xi'an 710032, China

Funds:

National Natural Science Foundation of China 82141104

More Information

Corresponding author:
WU Wenming, E-mail: wuwm@pumch.cn

NIE Yongzhan, E-mail: yongznie@fmmu.edu.cn

CHEN Jie, E-mail: chen0jie@hotmail.com
Received Date: October 17, 2022
Accepted Date: December 04, 2022
Available Online: January 15, 2023
Issue Publish Date: January 29, 2023

Graphical Abstract

Abstract

Abstract

Neuroendocrine neoplasms (NENs) are a group of malignancies arising from neuroendocrine cells and peptidergic neurons. The high heterogeneity of NENs leads to challenges and complexities in its diagnosis and treatment. Experts from relevant disciplines were convened by the Society of Neuroendocrine neoplasm of China Anti-Cancer Association to develop this first edition of the Chinese Guideline for diagnosis and treatment of NENs (2022) based on existing evidence combined with domestic and international guidelines and consensus. In this article, we summarize the important contents of this guideline and make further discussion on some controversial issues, with the aim to provide treatment reference in clinical practice.
- neuroendocrine neoplasms,
- diagnosis,
- treatment,
- guideline,
- interpretation

FullText(HTML)

References (38)

References

[1]	Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States[J]. JAMA Oncol, 2017, 3: 1335-1342. DOI: 10.1001/jamaoncol.2017.0589
[2]	Fang C, Wang W, Zhang Y, et al. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China[J]. Chin J Cancer, 2017, 36: 51. DOI: 10.1186/s40880-017-0218-3
[3]	Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Func-tional Pancreatic Neuroendocrine Tumors[J]. Neuroendocrinology, 2016, 103: 153-171. DOI: 10.1159/000443171
[4]	Kamilaris CDC, Stratakis CA. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis[J]. Front Endocrinol (Lausanne), 2019;10: 339. DOI: 10.3389/fendo.2019.00339
[5]	Puliani G, Di Vito V, Feola T, et al. NETest: A Systematic Review Focusing on the Prognostic and Predictive Role[J]. Neuroendocrinology, 2022, 112: 523-536. DOI: 10.1159/000518873
[6]	Malczewska A, Kos-Kudła B, Kidd M, et al. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors[J]. Adv Med Sci, 2020, 65: 18-29. DOI: 10.1016/j.advms.2019.10.002
[7]	Chen L, Guo Y, Zhang Y, et al. Development of a novel scoring system based on endoscopic appearance for management of rectal neuroendocrine tumors[J]. Endoscopy, 2021, 53: 702-709. DOI: 10.1055/a-1274-0161
[8]	Luo Y, Chen J, Huang K, et al. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?[J]. BMC Cancer, 2017, 17: 154. DOI: 10.1186/s12885-017-3150-7
[9]	Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_GETNE1504 study)[J]. Br J Cancer, 2019, 121: 537-544. DOI: 10.1038/s41416-019-0558-7
[10]	Chen L, Wang W, Jin K, et al. Special issue "the advane of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors[J]. Int J Cancer, 2023, 152: 90-99. DOI: 10.1002/ijc.34294
[11]	Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and ¹⁸F-FDG[J]. Cancer, 2008, 112: 2447-2455. DOI: 10.1002/cncr.23469
[12]	Panagiotidis E, Alshammari A, Michopoulou S, et al. Comparison of the Impact of ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors[J]. J Nucl Med, 2016, 58: 91-96.
[13]	Rinzivillo M, Partelli S, Prosperi D, et al. Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms[J]. Oncologist, 2018, 23: 186-192. DOI: 10.1634/theoncologist.2017-0278
[14]	Kim YI, Yoo C, Oh SJ, et al. Tumour-to-liver ratio determined by[(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours[J]. EJNMMI Res, 2020, 10: 63. DOI: 10.1186/s13550-020-00651-z
[15]	Kuik WJ, Kema IP, Brouwers AH, et al. In vivo biodistribution of no-carrier-added 6-¹⁸F-fluoro-3, 4-dihydroxy-L-phenylalanine (¹⁸F-DOPA), produced by a new nucleo-philic substitution approach, compared with carrier-added (¹⁸F-DOPA), prepared by conventional electrophilic substitution[J]. J Nucl Med, 2015, 56: 106-112. DOI: 10.2967/jnumed.114.145730
[16]	Piccardo A, Lopci E, Conte M, et al. Comparison of ¹⁸F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study[J]. Eur J Nucl Med Mol Imaging, 2012, 39: 57-71. DOI: 10.1007/s00259-011-1938-2
[17]	Luo Y, Pan Q, Yao S, et al. Glucagon-like Peptide-1 Receptor PET/CT with ⁶⁸Ga-NOTA-exendin-4 for Detecting Localized Insulinoma: a Prospective Cohort Study[J]. J Nucl Med, 2016, 57: 715-720. DOI: 10.2967/jnumed.115.167445
[18]	WHO Classification of Tumours Editorial Board. WHO classification of tumours, 5th Edition, Volume 1: Digestive System Tumours[M]. Lyon: IARC Press, 2019.
[19]	WHO Classification of Tumours Editorial Board. WHO Classification of Tumours, 5th Edition, Volume 5: Thoracic Tumours[M]. Lyon: IARC Press, 2021.
[20]	Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart[J]. J Thorac Oncol, 2015, 10: 1240-1242. DOI: 10.1097/JTO.0000000000000663
[21]	Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal[J]. Mod Pathol, 2018, 31: 1770-1786. DOI: 10.1038/s41379-018-0110-y
[22]	Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms[J]. Endocr Pathol, 2022, 33: 115-154. DOI: 10.1007/s12022-022-09708-2
[23]	Chivukula SV, Tierney JF, Hertl M, et al. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over-or undertreating patients?[J]. Surgery, 2020, 167: 180-186. DOI: 10.1016/j.surg.2019.04.061
[24]	Dong DH, Zhang XF, Poultsides G, et al. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm after curative resection: A multi-institutional study of 392 cases[J]. J Surg Oncol, 2019, 120: 1071-1079. DOI: 10.1002/jso.25716
[25]	Lopez-Aguiar AG, Zaidi MY, Beal EW, et al. Defining the role of lymphadenectomy for pancreatic neuroendocrine tumors: An eight-institution study of 695 patients from the US neuroendocrine tumor study group[J]. Ann Surg Oncol, 2019, 26: 2517-2524. DOI: 10.1245/s10434-019-07367-y
[26]	Guarneri G, de Mestier L, Landoni L, et al. Prognostic role of examined and positive lymph nodes after distal pancreatectomy for non-functioning neuroendocrine neoplasms[J]. Neuroendocrinology, 2021, 111: 728-738. DOI: 10.1159/000509709
[27]	Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med, 2014, 371: 224-233. DOI: 10.1056/NEJMoa1316158
[28]	Rinke A, Müller HH, Schade-Brittinger C, et al. PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroen-docrine midgut tumors: a report from the PROMID Study Group[J]. J Clin Oncol, 2009, 27: 4656-4663. DOI: 10.1200/JCO.2009.22.8510
[29]	Liu Y, Liu H, Chen W, et al. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden[J]. Cancer Med, 2022, 11: 2588-2600. DOI: 10.1002/cam4.4628
[30]	Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?[J]. J Hepatol, 2007, 47: 460-466. DOI: 10.1016/j.jhep.2007.07.004
[31]	中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)[J]. 中国癌症杂志, 2022, 32: 545-580. Society of Neuroendocrine Neoplasm of China Anti-Cancer Association. China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)[J]. Zhongguo Aizheng Zazhi, 2022, 32: 545-580.
[32]	Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas[J]. Neuroendocrinology, 2016, 103: 186-194. DOI: 10.1159/000443172
[33]	National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors (Version 2021)[EB/OL]. [2021-06-18]. https://www.nccn.org/guidelines/guidelines-detail?cate-gory=1&id=1448.
[34]	Bongiovanni A, Liverani C, Foca F, et al. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis[J]. Neuroendocrinology, 2021, 111: 895-906. DOI: 10.1159/000513218
[35]	Wang W, Zhang Y, Peng Y, et al. A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolo-mide Regimen in Neuroendocrine Neoplasms: A Retrospec-tive Multicenter Study[J]. Neuroendocrinology, 2021, 111: 752-763. DOI: 10.1159/000510159
[36]	Apostolidis L, Dal Buono A, Merola E, et al. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)[J]. Cancers, 2021, 13: 1936. DOI: 10.3390/cancers13081936
[37]	Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 379: 2220-2229. DOI: 10.1056/NEJMoa1809064
[38]	Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394: 1929-1939. DOI: 10.1016/S0140-6736(19)32222-6

Cited By

Cited by

Periodical cited type(7)

1.	朱玉佳，沈华，温奥楠，高梓翔，秦庆钊，单珅瑶，李文博，傅湘玲，赵一姣，王勇. 三维颌面对称参考平面智能构建的深度学习算法. 北京大学学报(医学版). 2025(01): 113-120 .
2.	王晓玲，范之劲，郭术廷. 医疗器械独立软件核查中对相关标准的思考. 中国医疗器械信息. 2024(11): 8-10+63 .
3.	中华医学会血液学分会实验诊断学组. 人工智能辅助血细胞形态学检查的技术要求及其临床应用中国专家共识(2024年版). 中华血液学杂志. 2024(04): 330-338 .
4.	萧毅，王培军，刘士远. 中国医学影像人工智能的过去、现在和未来. 中华放射学杂志. 2024(11): 1359-1364 .
5.	陈丹，闵锐，方鹏骞. 三级医院医学装备管理能力评估指标体系构建. 中国卫生质量管理. 2024(11): 61-65 .
6.	张楠，李静，张杰，杨炯，张政波，何昆仑. 智能化医疗设备测试方案探讨. 中国医疗器械杂志. 2024(06): 699-705 .
7.	曾雪晴，夏斌，曹战强，马天宇，许忞頔，徐子能，白海龙，丁鹏，朱俊霞. 基于深度学习的儿童曲面体层X线片牙齿数目异常识别模型的研发. 中华口腔医学杂志. 2023(11): 1138-1144 .

Other cited types(0)

Get Citation

PDF

XML

Article Metrics

Article views (1457) PDF downloads (500) Cited by(7)

Address：	Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
Tel：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
Copyright of website：	Editorial Office of Medical Journal of Peking Union Medical College Hospital

Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)

Abstract

References

Cited by

Periodical cited type(7)

Other cited types(0)

Catalog

Article Metrics

Related

Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)

Abstract

References

Cited by

Periodical cited type(7)

Other cited types(0)

Catalog

Article Metrics

Related

Export File

Citation

Format

Content